Global
COVID-19 Diagnostics Market Size was valued at USD 66.8 billion in 2021 and is
projected to decline at a compound annual growth rate (CAGR) of 6.82% during
the forecast period (2022 - 2030).
The
COVID-19 diagnostics market continues to evolve amidst global health
challenges. Rapid antigen tests and PCR-based methods remain pivotal in
detecting SARS-CoV-2, driving market growth. Technological advancements
emphasize accuracy, speed, and accessibility in testing solutions, fostering
demand for point-of-care testing devices and home testing kits. Regulatory
approvals and partnerships amplify market competition and innovation, with key
players expanding production capacities to meet escalating demands. Emerging
economies witness heightened adoption rates, spurred by government initiatives
and rising infection rates. However, supply chain disruptions and variant
uncertainties pose challenges. Market resilience persists as stakeholders
navigate evolving dynamics, prioritizing effective pandemic management
strategies.
The
COVID-19 Diagnostics Market has witnessed significant growth and innovation,
particularly with the emergence of rapid antigen tests and home influenza
tests. These advancements have revolutionized the way we detect and manage
respiratory illnesses, offering quicker results and enhanced convenience.
Antigen flu tests have become pivotal in the fight against
COVID-19, providing rapid and reliable detection of viral antigens in
respiratory specimens. These tests offer results in minutes, allowing for
prompt decision-making regarding patient care and disease management. With the
capacity to detect specific proteins on the surface of the virus, antigen flu
tests play a crucial role in identifying infected individuals swiftly, enabling
timely isolation and treatment.
Moreover,
the introduction of home influenza tests has empowered individuals to monitor
their health from the comfort of their homes. These tests are user-friendly and
provide accurate results, allowing individuals to quickly determine whether
they have influenza-like symptoms and take appropriate actions, such as seeking
medical advice or self-isolating to prevent the spread of illness.
As
the demand for efficient and accessible diagnostic solutions continues to rise,
the COVID-19 Diagnostics Market is poised for further expansion. With ongoing
research and development efforts aimed at improving test accuracy and
accessibility, antigen flu tests and home influenza tests are expected to play
an increasingly integral role in the global healthcare landscape, facilitating
effective disease containment and management.
Segment
Analysis
Global
COVID-19 Diagnostics Market has been segmented by Type, Technology, and End
Users. The market, based on type, has been bifurcated into molecular tests and
serology tests. On the basis of technology, the market has been bifurcated into
RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.
Based
on End User, the COVID-19 diagnostics market has been segregated into
hospitals, public health labs, private or commercial labs, and others.
Regional
Analysis
Global
COVID-19 Diagnostics Market, based on region, has been divided into the Europe,
Americas, Asia-Pacific, and the Middle East & Africa.
The
Europe is likely to dominate the global COVID-19 diagnostics market. This can
be attributed to the high COVID-19 morbidity and mortality observed among
residents in long-term care facilities (LTCF) in European Union (EU) and
European Economic Area (EEA) pose a major challenge for disease prevention and
control in such settings, which raises the demand for the wide availability of
diagnostics for immediate detection of COVID-19 cases. According to European
Centre for Disease Control and Prevention, 157 312 deaths in the EU/EEA and the
UK as of 19 May 2020 were reported. Moreover, the support from public &
private organizations in tackling COVID-19 is also expected to drive market
growth in the region.
The
American market for COVID-19 diagnostics is expected to be the second largest
during the forecast period. Rising product launches by major players and
ongoing public and private organizations' efforts to control the spread of the
virus is anticipated to drive the market growth. For instance, in March 2020,
the US FDA issued a EUA for a molecular point of care test kit by Abbott for
the rapid detection of COVID-19. Furthermore, the increasing numbers of corona
virus-positive cases also act as a driving factor and support market growth.
Asia-Pacific
is estimated to be the fastest-growing market. With an increasing number of
cases, governments across the Asia-Pacific countries are exploring the
opportunities of allowing private laboratories to ramp up testing, which is
boosting the market growth. For instance, In India, the Indian Council of
Medical Research (ICMR) has approved 51 private laboratories for COVID-19
testing on March 31, 2020. Moreover, the increasing number of COVID-19 cases is
also driving the market growth.
Key
Players
The
Global COVID-19 Diagnostics companies are Becton, Dickinson & Company (US),
Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F.
Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark
Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens
AG (Germany).
Related Reports:
suture wire
North America Sports
Therapies, Medicine and Betting
Refurbished Medical Devices
Brain Ischemia
Anal Cancer
For More Information, Please
Visit @ Market
Research Future
Comments
Post a Comment